FDA refuses to file Novo Nordisk application

The FDA has refused to start filing Novo Nordisk's application for an expanded marketing authorization for Ozempic in a higher dose.
Photo: Novo Nordisk Pharmatech/PR
Photo: Novo Nordisk Pharmatech/PR

Novo Nordisk has received a Refusal to File letter from the US Food and Drug Administration (FDA) for its application for a version of Ozempic, which Novo Nordisk announces on Monday evening.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must contain at least 6 characters
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading